In-licensed and advanced molecular imaging development programs in three areas: Alzheimer's disease, Parkinson's disease and diabetes
Completed license-option agreement with Bayer Schering Pharma for PET amyloid imaging compound.
Secured collaborations with four pharmaceutical partners, including several top tier global pharma companies.
Raised $9M in Series A/B financing
Assembled world class development team and established a state-of-the-art R&D lab.
Developed robust pipeline of clinical development compounds from technology in-licensed from the University of Pennsylvania and the University of Michigan.
Raised $26M Series C financing.
Selected and advanced development compounds into Phase III clinical trials for imaging β-amyloid in Alzheimer's disease and VMAT2 in Phase II for Parkinson's disease, dementia with Lewy bodies, as well as early stage clinical studies in diabetes.
Established strong IP position in support of pipeline programs.
Raised $34.5M in series D funding and hired Commercialization leader.
